Press Releases May 1, 2026 04:45 PM

CN Announces Election of Directors

CN Announces Re-election of All Director Nominees and Board Chair at Annual Shareholders Meeting

By Jordan Park
Share
Twitter Reddit Facebook LinkedIn
CNI

CN has announced the election of all eleven director nominees at its Annual Meeting of Shareholders, with Shauneen Bruder unanimously re-elected as board chair. Detailed voting results show strong support for all nominees. The company is a major North American rail operator, contributing significantly to transportation of goods across Canada and the U.S.

CN Announces Election of Directors
CNI
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • All 11 director nominees were elected with strong majority support, reflecting shareholder confidence.
  • Shauneen Bruder re-elected unanimously as board chair, ensuring continuity in leadership and governance.
  • CN operates a nearly 20,000-mile rail network crucial for North American trade, impacting transportation and logistics sectors.

MONTREAL, May 01, 2026 (GLOBE NEWSWIRE) -- CN (TSX: CNR) (NYSE: CNI) announced that the director nominees listed in the management information circular dated March 9, 2026 (the “Information Circular”), were elected as directors of CN. The detailed results of the vote for the election of directors held at CN’s Annual Meeting of Shareholders (“Meeting”) on May 1, 2026 via online webcast are set out below.

Election of Directors

On a vote by ballot, each of the following 11 nominees proposed by management was elected as a director of CN:

NomineeVotes For % ForVotes
Against
 %
Against
Shauneen Bruder438,986,975 96.07%17,962,676 3.93%Jo-ann dePass Olsovsky430,546,313 94.22%26,403,335 5.78%David Freeman455,482,343 99.68%1,467,306 0.32%Denise Gray439,516,285 96.18%17,433,244 3.82%Justin M. Howell438,989,575 96.07%17,959,954 3.93%Susan C. Jones454,848,008 99.54%2,101,520 0.46%Robert Knight438,972,788 96.07%17,976,737 3.93%Michel Letellier453,567,551 99.26%3,381,977 0.74%Al Monaco452,819,045 99.10%4,130,419 0.90%Madeleine Paquin455,415,305 99.66%1,534,223 0.34%Tracy Robinson455,394,959 99.66%1,555,622 0.34%


Shauneen Bruder was unanimously re-elected by the board of directors as board chair. Ms. Bruder is a Corporate Director and retired Executive Vice-President, Operations at the Royal Bank of Canada.

Biographical information on all directors can be found in the Information Circular, available at https://www.cn.ca/en/investors/regulatory-filings/

Final voting results on all matters voted on at the Meeting will be filed with the Canadian and U.S. securities regulators.

About CN
CN powers the economy by safely transporting more than 300 million tons of natural resources, manufactured products, and finished goods throughout North America every year for its customers. With its nearly 20,000-mile rail network and related transportation services, CN connects Canada’s Eastern and Western coasts with the U.S. Midwest and the U.S. Gulf Coast, contributing to sustainable trade and the prosperity of the communities in which it operates since 1919.

Contacts: 

MediaInvestment CommunityAshley MichnowskiJamie LockwoodSenior ManagerVice-PresidentMedia RelationsInvestor Relations & Special Projects(438) 596-4329(514) 399-0052
media@cn.cainvestor.relations@cn.ca



Risks

  • Potential governance and leadership challenges if board dynamics change in the future.
  • Regulatory risks given the company's cross-border operations between Canada and the U.S.
  • Economic or trade disruptions affecting demand for rail transportation services, impacting CN's revenue.

More from Press Releases

Crinetics Presents Long Term Data at ENDO 2026 Confirming PALSONIFY™ (paltusotine) Provides Durable, Consistent Acromegaly Control Jun 14, 2026 Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual Meeting Jun 14, 2026 Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2 VIBRANT Trial at EAACI 2026 Jun 14, 2026 Mineralys Therapeutics Presents Late-Breaking Data on Lorundrostat and Heart Failure Risk Biomarkers at The Endocrine Society Annual Meeting (ENDO 2026) Jun 14, 2026 Celldex Presents Positive First-in-Human Results from Phase 1 Study of Novel Bispecific CDX-622 at the European Academy of Allergy and Clinical Immunology Annual Meeting Jun 14, 2026